CABA
Cabaletta Bio, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website cabalettabio.com
- Employees(FY) 92
- ISIN US12674W1099
Performance
+13.48%
1W
-28.86%
1M
-48.79%
3M
-24.92%
6M
-46.78%
YTD
+3.25%
1Y
Profile
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Investment Analysis Report: CABA
Overview
In this investment analysis report, we will delve into the financial statements of CABA, a company operating in the Health Technology sector within the Biotechnology industry. We will analyze the company's valuation, financial health, earnings and revenue growth, profitability, operating margin, operatin...
Technical Analysis of CABA 2024-05-03
Overview:
In analyzing the technical indicators for CABA over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day MA has been consistently below the closing prices, in...
Recent News & Updates
- 2024-03-23 05:31
- 2024-03-21 07:00
- 2024-03-21 01:53
CABA Stock Earnings: Cabaletta Bio Misses EPS for Q4 2023(Investorplace)
- 2024-03-20 19:00
- 2024-03-20 07:00
- 2024-03-19 19:00
- 2024-03-08 08:50
Jim Cramer’s 10 Latest Stock Picks This Week(Insider Monkey)
- 2024-03-07 19:50
Jim Cramer's 10 Latest Stock Picks This Week(Insidermonkey)
- 2024-02-27 10:11
- 2024-02-27 08:00
- 2024-02-26 21:11
- 2024-02-26 19:00
- 2024-02-01 16:30
- 2024-02-01 03:30
- 2024-01-31 08:00
- 2024-01-30 19:00
- 2024-01-09 06:27
Are Investors Undervaluing Cabaletta Bio, Inc. (NASDAQ:CABA) By 47%?(Simply Wall St.)
- 2024-01-08 07:00
- 2024-01-07 18:00
- 2024-01-02 19:00
- 2024-01-02 08:00
- 2023-12-18 20:49
- 2023-11-28 16:30
- 2023-11-28 03:30
- 2023-11-09 08:10
- 2023-11-09 07:00
- 2023-11-08 18:00
- 2023-11-06 08:15
- 2023-11-06 07:00
- 2023-11-05 19:15
Page 1 of 5
previousnext